Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Patients' perspectives on COPD: findings from a social media listening study.

Cook NS, Kostikas K, Gruenberger JB, Shah B, Pathak P, Kaur VP, Mudumby A, Sharma R, Gutzwiller FS.

ERJ Open Res. 2019 Feb 11;5(1). pii: 00128-2018. doi: 10.1183/23120541.00128-2018. eCollection 2019 Feb.

PMID:
30775374
2.

Serum levels of hyaluronic acid are associated with COPD severity and predict survival.

Papakonstantinou E, Bonovolias I, Roth M, Tamm M, Schumann D, Baty F, Louis R, Milenkovic B, Boersma W, Stieltjes B, Kostikas K, Blasi F, Aerts JG, Rohde GGU, Lacoma A, Torres A, Welte T, Stolz D.

Eur Respir J. 2019 Feb 14. pii: 1801183. doi: 10.1183/13993003.01183-2018. [Epub ahead of print]

PMID:
30705130
3.

Microbiota and asthma: Clinical implications.

Katsoulis K, Ismailos G, Kipourou M, Kostikas K.

Respir Med. 2019 Jan;146:28-35. doi: 10.1016/j.rmed.2018.11.016. Epub 2018 Nov 22. Review. No abstract available.

PMID:
30665515
4.

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.

Wedzicha JA, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, Shen S, Goyal P, Mezzi K, Kostikas K.

Respir Res. 2019 Jan 8;20(1):4. doi: 10.1186/s12931-019-0972-7.

5.

Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion.

Chapman KR, Hurst JR, Fogel RB, Pfister P, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2019 Feb 1;199(3):390-392. doi: 10.1164/rccm.201809-1776LE. No abstract available.

6.

Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients.

Ställberg B, Janson C, Larsson K, Johansson G, Kostikas K, Gruenberger JB, Gutzwiller FS, Jorgensen L, Uhde M, Lisspers K.

NPJ Prim Care Respir Med. 2018 Sep 10;28(1):33. doi: 10.1038/s41533-018-0101-y.

7.

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.

Buhl R, Criée CP, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 24;13:2557-2568. doi: 10.2147/COPD.S169958. eCollection 2018.

8.

Revisiting IL-13 blockade: can we reach the wonderland the inhaled way?

Papaioannou AI, Loukides S, Kostikas K.

EBioMedicine. 2018 Sep;35:6-7. doi: 10.1016/j.ebiom.2018.08.013. Epub 2018 Aug 14. No abstract available.

9.

Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Wedzicha JA, Banerji D, Kostikas K.

N Engl J Med. 2018 Aug 9;379(6):591. doi: 10.1056/NEJMc1807380. No abstract available.

PMID:
30091348
10.

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.

Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV; FLASH Investigators.

Respirology. 2018 Dec;23(12):1152-1159. doi: 10.1111/resp.13374. Epub 2018 Aug 3.

PMID:
30074294
11.

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.

Frent SM, Chapman KR, Larbig M, Mackay A, Fogel R, Gutzwiller FS, Shen S, Patalano F, Banerji D, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):43-51. doi: 10.1164/rccm.201801-0038OC.

12.

Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease.

Schumann DM, Leeming D, Papakonstantinou E, Blasi F, Kostikas K, Boersma W, Louis R, Milenkovic B, Aerts J, Sand JMB, Wouters EFM, Rohde G, Prat C, Torres A, Welte T, Tamm M, Karsdal M, Stolz D.

Chest. 2018 Oct;154(4):798-807. doi: 10.1016/j.chest.2018.06.028. Epub 2018 Jun 30.

PMID:
29966667
13.

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

Anzueto AR, Kostikas K, Mezzi K, Shen S, Larbig M, Patalano F, Fogel R, Banerji D, Wedzicha JA.

Respir Res. 2018 Jun 20;19(1):121. doi: 10.1186/s12931-018-0830-z.

14.

Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.

Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-339. doi: 10.1164/rccm.201803-0405OC.

15.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

16.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

17.

Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations.

Mackay AJ, Kostikas K, Murray L, Martinez FJ, Miravitlles M, Donaldson G, Banerji D, Patalano F, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):730-738. doi: 10.1164/rccm.201712-2482CI.

18.

Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.

Kostikas K, Aalamian-Mattheis M, Pagano VA, Nunez X, Fogel R, Patalano F, Clemens A.

COPD. 2018 Apr;15(2):185-191. doi: 10.1080/15412555.2018.1445213. Epub 2018 Apr 16. Erratum in: COPD. 2018 Jun;15(3):313.

PMID:
29658810
19.

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Petta V, Loukides S, Kostikas K, Papaioannou AI, Papatheodorou G, Cholidou K, Tomos I, Papiris S, Koulouris NG, Bakakos P.

J Thorac Dis. 2018 Feb;10(2):740-748. doi: 10.21037/jtd.2018.01.45.

20.

IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes.

Egli A, Mandal J, Schumann DM, Roth M, Thomas B, Lorne Tyrrell D, Blasi F, Kostikas K, Boersma W, Milenkovic B, Lacoma A, Rentsch K, Rohde GGU, Louis R, Aerts JG, Welte T, Torres A, Tamm M, Stolz D.

BMC Pulm Med. 2018 Mar 21;18(1):51. doi: 10.1186/s12890-018-0616-6.

21.

Serum Surfactant Protein Levels in Patients Admitted to the Hospital with Acute COPD Exacerbation.

Papaioannou AI, Konstantelou E, Papaporfyriou A, Bartziokas K, Spathis A, Bakakos P, Loukides S, Koulouris N, Papiris S, Kostikas K.

Lung. 2018 Apr;196(2):201-205. doi: 10.1007/s00408-018-0099-5. Epub 2018 Feb 14.

PMID:
29445934
22.

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD.

Kostikas K, Brindicci C, Patalano F.

Curr Drug Targets. 2018;19(16):1882-1896. doi: 10.2174/1389450119666180212120012.

23.

At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.

Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, Celli BR, Christenson SA, Crystal RG, Fagerås M, Freeman CM, Groenke L, Hoffman EA, Kesimer M, Kostikas K, Paine R 3rd, Rafii S, Rennard SI, Segal LN, Shaykhiev R, Stevenson C, Tal-Singer R, Vestbo J, Woodruff PG, Curtis JL, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540-1551. doi: 10.1164/rccm.201710-2028PP. No abstract available. Erratum in: Am J Respir Crit Care Med. 2018 Dec 1;198(11):1463.

24.

Using simple blood count for the diagnosis of pulmonary embolism in chronic obstructive pulmonary disease exacerbations: are we there yet?

Papaioannou AI, Papiris S, Kostikas K.

Pol Arch Intern Med. 2018 Jan 31;128(1):7-8. doi: 10.20452/pamw.4195. Epub 2018 Jan 29. No abstract available.

25.

Exhaled breath temperature in optimally treated asthmatics: severity and underlying mechanisms.

Ntontsi P, Bakakos P, Papathanasiou E, Tsilogianni Z, Kostikas K, Hillas G, Papatheodorou G, Koulouris N, Papiris S, Loukides S.

J Breath Res. 2018 Feb 20;12(2):026013. doi: 10.1088/1752-7163/aa9d46.

PMID:
29176061
26.

Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study.

Papaioannou AI, Kostikas K, Papaporfyriou A, Angelakis L, Papathanasiou E, Hillas G, Mazioti A, Bakakos P, Koulouris N, Papiris S, Loukides S.

COPD. 2017 Dec;14(6):635-640. doi: 10.1080/15412555.2017.1386644. Epub 2017 Nov 3.

PMID:
29099646
27.

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR.

Am J Respir Crit Care Med. 2018 May 1;197(9):1223-1226. doi: 10.1164/rccm.201709-1822LE. No abstract available.

PMID:
29099609
28.

Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD.

Mandal J, Roth M, Papakonstantinou E, Sun Q, Costa L, Boeck L, Scherr A, Rakic J, Louis R, Milenkovic B, Boersma W, Kostikas K, Blasi F, Aerts J, Rohde G, Lacoma A, Torres A, Welte T, Tamm M, Stolz D.

Pulm Pharmacol Ther. 2018 Feb;48:111-116. doi: 10.1016/j.pupt.2017.10.011. Epub 2017 Oct 21.

PMID:
29066215
29.

The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis.

Tsikrika S, Dimakou K, Papaioannou AI, Hillas G, Thanos L, Kostikas K, Loukides S, Papiris S, Koulouris N, Bakakos P.

Cytokine. 2017 Nov;99:281-286. doi: 10.1016/j.cyto.2017.08.005. Epub 2017 Aug 31.

PMID:
28863927
30.

Prevalence of lung function impairment among Greek cement production workers: a cross-sectional study.

Rachiotis G, Kostikas K, Pinotsi D, Hadjichristodoulou C, Drivas S.

Ind Health. 2018 Feb 7;56(1):49-52. doi: 10.2486/indhealth.2017-0005. Epub 2017 Aug 22.

31.

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators.

Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.

32.

Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.

Tsiligianni I, Mezzi K, Fucile S, Kostikas K, Shen S, Banerji D, Fogel R.

COPD. 2017 Aug;14(4):375-381. doi: 10.1080/15412555.2017.1324837. Epub 2017 Jun 8.

PMID:
28594587
33.

Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits.

Vasilopoulou M, Papaioannou AI, Kaltsakas G, Louvaris Z, Chynkiamis N, Spetsioti S, Kortianou E, Genimata SA, Palamidas A, Kostikas K, Koulouris NG, Vogiatzis I.

Eur Respir J. 2017 May 25;49(5). pii: 1602129. doi: 10.1183/13993003.02129-2016. Print 2017 May.

34.

Serum periostin in patients hospitalized for COPD exacerbations.

Konstantelou E, Papaioannou AI, Loukides S, Bartziokas K, Papaporfyriou A, Papatheodorou G, Bakakos P, Papiris S, Koulouris N, Kostikas K.

Cytokine. 2017 May;93:51-56. doi: 10.1016/j.cyto.2017.05.007. Epub 2017 May 13.

PMID:
28511944
35.

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.

Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.

Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017.

36.

A European Respiratory Society technical standard: exhaled biomarkers in lung disease.

Horváth I, Barnes PJ, Loukides S, Sterk PJ, Högman M, Olin AC, Amann A, Antus B, Baraldi E, Bikov A, Boots AW, Bos LD, Brinkman P, Bucca C, Carpagnano GE, Corradi M, Cristescu S, de Jongste JC, Dinh-Xuan AT, Dompeling E, Fens N, Fowler S, Hohlfeld JM, Holz O, Jöbsis Q, Van De Kant K, Knobel HH, Kostikas K, Lehtimäki L, Lundberg J, Montuschi P, Van Muylem A, Pennazza G, Reinhold P, Ricciardolo FLM, Rosias P, Santonico M, van der Schee MP, van Schooten FJ, Spanevello A, Tonia T, Vink TJ.

Eur Respir J. 2017 Apr 26;49(4). pii: 1600965. doi: 10.1183/13993003.00965-2016. Print 2017 Apr.

37.

Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes.

Ntontsi P, Loukides S, Bakakos P, Kostikas K, Papatheodorou G, Papathanassiou E, Hillas G, Koulouris N, Papiris S, Papaioannou AI.

Allergy. 2017 Nov;72(11):1761-1767. doi: 10.1111/all.13184. Epub 2017 May 11.

PMID:
28407269
38.

The association between serum periostin and a type 2 helper airway composite index in optimally treated asthmatics.

Konstantellou E, Loukides S, Ntontsi P, Papathanasiou E, Kostikas K, Paptheodorou G, Hillas G, Papiris S, Koulouris NG, Bakakos P.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1129-1131.e3. doi: 10.1016/j.jaip.2017.03.005. Epub 2017 Apr 7. No abstract available.

PMID:
28396112
39.

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 17;12:907-922. doi: 10.2147/COPD.S130482. eCollection 2017. Review.

40.

Prevalence and determinants of current and secondhand smoking in Greece: results from the Global Adult Tobacco Survey (GATS) study.

Rachiotis G, Barbouni A, Katsioulis A, Antoniadou E, Kostikas K, Merakou K, Kourea K, Khoury RN, Tsouros A, Kremastinou J, Hadjichristodoulou C.

BMJ Open. 2017 Jan 19;7(1):e013150. doi: 10.1136/bmjopen-2016-013150.

41.

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.

Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, Sigrist T, Fitting JW, Schmidt U, Geiser T, Wild C, Kostikas K, Clemens A, Brutsche M.

Respir Res. 2017 Jan 11;18(1):13. doi: 10.1186/s12931-016-0498-1.

42.

How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):139-149. doi: 10.1164/rccm.201609-1794CI. Review.

43.

Activin A and follistatin in patients with asthma. Does severity make the difference?

Papaporfyriou A, Bakakos P, Kostikas K, Papatheodorou G, Hillas G, Trigidou R, Katafigiotis P, Koulouris NG, Papiris SA, Loukides S.

Respirology. 2017 Apr;22(3):473-479. doi: 10.1111/resp.12937. Epub 2016 Nov 2.

PMID:
27807906
44.

Sputum interleukin-13 as a biomarker for the evaluation of asthma control.

Tsilogianni Z, Hillas G, Bakakos P, Aggelakis L, Konstantellou E, Papaioannou AI, Papaporfyriou A, Papiris S, Koulouris N, Loukides S, Kostikas K.

Clin Exp Allergy. 2016 Nov;46(11):1498. doi: 10.1111/cea.12825. No abstract available.

PMID:
27790845
45.

Quantitative computed tomography: what does airway obstruction look-like?

Kallieri M, Papaioannou AI, Kostikas K, Bakakos P, Loukides S.

J Thorac Dis. 2016 Sep;8(9):E1044-E1046. No abstract available.

46.

The role of endosomal toll-like receptors in asthma.

Papaioannou AI, Spathis A, Kostikas K, Karakitsos P, Papiris S, Rossios C.

Eur J Pharmacol. 2017 Aug 5;808:14-20. doi: 10.1016/j.ejphar.2016.09.033. Epub 2016 Sep 24. Review.

PMID:
27677226
47.

Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD.

Stolz D, Leeming DJ, Kristensen JHE, Karsdal MA, Boersma W, Louis R, Milenkovic B, Kostikas K, Blasi F, Aerts J, Sand JMB, Wouters EFM, Rohde G, Prat C, Torres A, Welte T, Roth M, Papakonstantinou E, Tamm M.

Chest. 2017 Jan;151(1):47-59. doi: 10.1016/j.chest.2016.08.1440. Epub 2016 Aug 26.

48.

25-hydroxyvitamin D in malignant pleural disease: a prospective cohort study.

Panagiotou M, Papaioannou AI, Kostikas K, Takou A, Paraskeva M, Kalkanis A, Diamantea F, Kastanakis E, Maropoulos G, Filaditaki V, Karagianidis N.

Clin Respir J. 2018 Feb;12(2):467-473. doi: 10.1111/crj.12540. Epub 2016 Aug 22.

PMID:
27502152
49.

Predictors of future exacerbation risk in patients with asthma.

Papaioannou AI, Kostikas K, Bakakos P, Papaporfyriou A, Konstantellou E, Hillas G, Papatheodorou G, Koulouris NG, Papiris S, Loukides S.

Postgrad Med. 2016 Sep;128(7):687-92. doi: 10.1080/00325481.2016.1220807. Epub 2016 Aug 17.

PMID:
27494758
50.

Combined pulmonary fibrosis and emphysema: The many aspects of a cohabitation contract.

Papaioannou AI, Kostikas K, Manali ED, Papadaki G, Roussou A, Kolilekas L, Borie R, Bouros D, Papiris SA.

Respir Med. 2016 Aug;117:14-26. doi: 10.1016/j.rmed.2016.05.005. Epub 2016 May 7. Review.

Supplemental Content

Loading ...
Support Center